What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025Blood

Efficacy and safety of the antithrombin siRNA fitusiran as prophylaxis in haemophilia a and B: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Fitusiran significantly reduces annualised bleeding rates, suggesting a transformative potential for haemophilia management.
The meta-analysis showed a mean difference of -3.45 in annualised bleeding rates with fitusiran treatment.
Observational analysis across multiple RCTs suggests that fitusiran's efficacy does not correlate with increased adverse effects.
Findings support integration of fitusiran in clinical practice guidelines for treating haemophilia A and B.

No takes yet. Share an insight, caveat, or question.

Systematic review reveals fitusiran significantly reduces bleeding rates in haemophilia B, indicating it could transform treatment practices.

Nasir et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Systematic review reveals fitusiran significantly reduces bleeding rates in haemophilia B, indicating it could transform treatment practices.